Vascular Permeability Factor/Vascular Endothelial Cell Growth Factor-mediated Permeability Occurs through Disorganization of Endothelial Junctional Proteins*
- From the Departments of ‡Molecular and Cellular Physiology and §Medicine, Louisiana State University Medical Center, Shreveport, Louisiana 71130
Abstract
Vascular permeability factor/vascular endothelial growth factor stimulates endothelial proliferation, angiogenesis, and increased vascular permeability in vivo. We investigated mechanisms of vascular permeability factor-mediated endothelial monolayer permeability changes in vitro. [14C]Albumin flux across endothelial monolayers was measured following a 90-min exposure to vascular permeability factor (660 pm). Vascular permeability factor increased albumin flux to 3.4 times that of control albumin flux. Endothelial monolayers were also incubated for 90 min with vascular permeability factor plus Gö6976 (10 nm), staurosporine (1 μm), wortmannin (10 nm), AG126 (1 and 2.67 μm), and PD98059 (20 μm). Vascular permeability factor-mediated permeability was not blocked by Gö6976, an antagonist of “classical” protein kinase C, staurosporine, a pan-protein kinase C antagonist, nor wortmannin, a PI3-kinase blocker, but was blocked by incubation with AG126 or PD98059, inhibitors of mitogen-activated protein kinase activation. Immunofluorescent staining of the junctional proteins VE-cadherin and occludin showed a loss of these proteins from the endothelial junction that was prevented by co-incubation with AG126 or PD98059. These data demonstrate that vascular permeability factor increases albumin permeability across endothelial monolayers in vitro and suggests that permeability increases through rearrangement of endothelial junctional proteins involving the mitogen-activated protein kinase signal transduction pathway.
Footnotes
-
↵* This work was supported by National Institutes of Health Grants HL47615 and DK43785.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵¶ To whom correspondence should be addressed: Dept. of Molecular and Cellular Physiology, LSU Medical Center-Shreveport, 1501 Kings Hwy., Shreveport, LA 71130-3932. Tel.: 318-675-4151; Fax: 318-675-4156; E-mail: salexa{at}mail-sh.lsumc.edu.
-
↵1 The abbreviations used are: VPF, vascular permeability factor/vascular endothelial growth factor; HUVEC, human umbilical vein endothelium cells; PI3-kinase, phosphatidylinositol 3′-kinase; PLCγ, phospholipase Cγ; PKC, protein kinase C; MAP, mitogen-activated protein; DMEM, Dulbecco’s modified Eagle’s medium.
-
- Received February 20, 1998.
- Revision received April 8, 1998.
- The American Society for Biochemistry and Molecular Biology, Inc.











